OncRef

Clinical Trial: NCT06300424

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Guangdong Provincial People's Hospital
Information Provided By:Guangdong Provincial People's Hospital
Last Update Posted:2026-04-29

Study Overview

Brief Summary

Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.

Official Title

Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study

Conditions

Non Small Cell Lung Cancer, EGFR Gene Mutation

Intervention / Treatment

  • Drug: almonertinib
  • Drug: Carboplatin
  • Drug: Nab paclitaxel

Other Study ID Numbers

  • KY2024-162

Start Date (Actual)

2024-04-01

Primary Completion Date (Actual)

2026-01-26

Study Completion Date (Estimated)

2026-04-30

Enrollment (Estimated)

32

Study Type

Interventional

Phase

Phase 2